News

Filter

Current filters:

PfizerCardio-vascular

1 to 9 of 99 results

Portola’s andexanet alfa reverses Eliquis anticoagulant effect

Portola’s andexanet alfa reverses Eliquis anticoagulant effect

17-12-2014

A Phase III clinical trial has found that Portola Pharmaceuticals' andexanet alfa reverses the effects…

andexanet alfaBristol-Myers SquibbCardio-vascularEliquisPfizerPharmaceuticalPortola PharmaceuticalsResearchUSA

Mixed findings from IQWiG on added benefit for Eliquis

05-12-2014

The German Institute for Quality and Efficiency in Health Care (IQWiG) has examined a dossier on Eliquis…

Bristol-Myers SquibbCardio-vascularEliquisGermanyPfizerPharmaceuticalPricingRegulation

Viagra found to have potential as heart disease treatment

20-10-2014

Blockbuster erectile dysfunction drug Viagra (sildenafil) could be used as a safe treatment for heart…

Cardio-vascularPfizerPharmaceuticalResearchsildenafilViagra

FDA expands indication for Eliquis to treatment of DVT and PE

FDA expands indication for Eliquis to treatment of DVT and PE

22-08-2014

US pharma majors Bristol-Myers Squibb and Pfizer late yesterday said that the US Food and Drug Administration…

Boehringer IngelheimCardio-vascularEliquisPfizerPharmaceuticalPulmonary embolismRegulationUSA

New indications approved in EU for Bristol-Myers/Pfizer Eliquis

New indications approved in EU for Bristol-Myers/Pfizer Eliquis

30-07-2014

The European Commission has approved US pharma majors Bristol-Myers Squibb and Pfizer’s Eliquis (apixaban)…

Bristol-Myers SquibbCardio-vascularEliquisEuropePfizerPharmaceuticalRegulation

Acute coronary syndrome treatment market to more than triple by 2023

Acute coronary syndrome treatment market to more than triple by 2023

30-07-2014

The launch of several drugs with “extraordinary blockbuster potential” will cause the acute coronary…

Acute coronary syndromealirocumabAmgenBayerCardio-vascularEuropeevolocumabJapanMarkets & MarketingMerck & CoPfizerPharmaceuticalSanofiUSAXareltoZontivity

Brazil and Mexico physicians’ preferences on anticoagulants

25-07-2014

Novel oral anticoagulants (NOACs) such as Bayer’s Xarelto (rivaroxaban), Boehringer Ingelheim’s Pradaxa…

BayerBoehringer IngelheimBrazilBristol-Myers SquibbCardio-vascularEliquisMarkets & MarketingMexicoPfizerPharmaceuticalPradaxaPricingXarelto

1 to 9 of 99 results

COMPANY SPOTLIGHT

Menarini

Back to top